Dosing & Uses
Dosage Forms & Strengths
0.03% or 0.1% ointment: Apply thin layer to affected area q12hr; discontinue treatment when symptoms have cleared; if no improvement within 6 weeks, reassess diagnosis
Dosage Forms & Strengths
<2 years old: Not recommended
2-15 years: 0.03% ointment: Apply thin layer to affected area q12hr
>15 years: Apply 0.03% or 0.1% ointment as thin layer to affected area q12hr; discontinue treatment when symptoms have cleared; if no improvement within 6 weeks, reassess diagnosis
Burning sensation (43-58%)
Flu-like symptoms (23-31%)
Skin erythema (12-28%)
Infections: Bullous impetigo, osteomyelitis, septicemia
Neoplasms: Lymphomas, basal cell carcinoma, squamous cell carcinoma, malignant melanoma
Renal: Acute renal failure in patients with or without Netherton’s syndrome, renal impairment
Skin: Rosacea, application site edema
Black Box Warnings
Rare cases of malignancy reported (although causal relationship not identified)
Avoid long-term use and limit application to areas of atopic dermatitis
Not indicated for use in children <2 yr
Only 0.03% ointment indicated for children aged 2-15 years
Age <2 yr
Preferably use as second-line agents for short-term & intermittent treatment in unresponsive to, or intolerant of other treatments
Do not use with occlusive dressings
May be associated with development of lymphadenopathy
Not for application in areas with active viral or bacterial infections
Acute renal failure reported (rare)
Potential risk of lymphoma and skin cancer
Not recommended in patients having skin conditions with a skin barrier defect where there is the potential for increased systemic absorption of tacrolimus (eg, Netherton's syndrome, lamellar ichthyosis, generalized erythroderma, cutaneous graft vs host disease)
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Not known whether tacrolimus is distributed in milk following topical administration to skin
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Unknown; inhibits T-cell activation by binding to intracellular protein FKBP-12 and complexes with calcineurin dependent proteins
Absorption: No systemic absorption detected
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.